Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) POLE Antibodies:
anti-Human POLE Antibodies:
anti-Mustelid POLE Antibodies:
Go to our pre-filtered search.
Human Monoclonal POLE Primary Antibody for ICC, IF - ABIN151041
Maga, Jónsson, Stucki, Spadari, Hübscher: Dual mode of interaction of DNA polymerase epsilon with proliferating cell nuclear antigen in primer binding and DNA synthesis. in Journal of molecular biology 1999
Show all 12 Pubmed References
A missense mutation in Rev7 (show MAD2L2 Antibodies) disrupts formation of Polzeta, impairing mouse development and repair of genotoxic agent-induced DNA lesions.
Mutation in DNA Polymerase II (show POLA2 Antibodies) gene is associated with MMR (show MRC1 Antibodies) deficiency in cancer.
This is the first study to functionally analyze a POLE genetic variant outside the exonuclease (show EXO1 Antibodies) domain and widens the spectrum of genetic changes in this DNA polymerase (show POLB Antibodies) that could lead to colorectal cancer predisposition.
POLE exonuclease (show EXO1 Antibodies) domain mutations are prognostic markers associated with excellent outcomes for endometrial carcinoma patients.
Germline PMS2 (show PMS2 Antibodies) and somatic POLE exonuclease (show EXO1 Antibodies) mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours
Hypermutation and elevated neoantigen count in glioblastoma occurred in a patient harboring a germline POLE mutation and are associated with a clinical and antitumor immune response to PD-1 (show PDCD1 Antibodies) blockade
Human CTF18-RFC clamp-loader complexed with non-synthesising POLE efficiently loads the PCNA sliding clamp.
POLE-mutated undifferentiated and dedifferentiated endometrial carcinomas were more frequently stage I tumors than similar carcinomas lacking exonuclease (show EXO1 Antibodies) domain mutations (7/9; 78% vs. 3/12; 25%; P=0.023) and patients had significantly better outcome (disease-specific survival) than those without POLE exonuclease (show EXO1 Antibodies) domain mutations (P=0.02)
Germline or somatic variants in the POLE/POLD1 (show POLD1 Antibodies) were identified in unresolved suspected Lynch syndrome cancers with mismatch repair defect.
In colorectal cancers, mutations in the FBXW7 gene were more common in the younger cohort (27.5% vs 9.7%; P = .0022) as were mutations in the proofreading domain of polymerase epsilon catalytic subunit (POLE) (9.8% vs 1%; P = .0048).
POLE ultra-mutated endometrial-carcinomas are heavily infiltrated with CD4 (show CD4 Antibodies)+/CD8 (show CD8A Antibodies)+ TIL (show TLR1 Antibodies), overexpress PD-1 (show PDCD1 Antibodies) immune-check-point, and have a better prognosis when compared to other molecular subtypes of endometrial-carcinomas patients. POLE-mutated tumor-cell lines are resistant to platinum-chemotherapy in-vitro suggesting that the better prognosis of POLE-patients is not secondary to a higher sensitivity to ch
Participates in DNA repair and in chromosomal DNA replication.
DNA polymerase II subunit A
, DNA polymerase epsilon catalytic subunit A
, DNA-directed DNA polymerase epsilon